{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T20:21:46Z","timestamp":1725826906211},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40265-013-0048-9","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T08:35:31Z","timestamp":1367829331000},"page":"703-713","source":"Crossref","is-referenced-by-count":7,"title":["Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (HibMenCY-TT; MenHibrix\u00ae): A Review"],"prefix":"10.1007","volume":"73","author":[{"given":"Caroline M.","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"48_CR1","unstructured":"World Health Organization. New and under-utilized vaccines implementation (NUVI). 2012. http:\/\/www.who.int\/nuvi\/meningitis\/en\/index.html . Accessed 22 Mar 2013."},{"key":"48_CR2","unstructured":"World Health Organization. Bacterial meningitis (including Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae). 2012. http:\/\/www.who.int\/immunization_monitoring\/diseases\/meningitis_surveillance\/en . Accessed 22 Mar 2013."},{"issue":"22","key":"48_CR3","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","volume":"24","author":"MP Girard","year":"2006","unstructured":"Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24(22):4692\u2013700.","journal-title":"Vaccine."},{"issue":"1","key":"48_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/504804","volume":"43","author":"R Brooks","year":"2006","unstructured":"Brooks R, Woods C, Benjamin D Jr, et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994\u20132002. Clin Infect Dis. 2006;43(1):49\u201354.","journal-title":"Clin Infect Dis."},{"issue":"Suppl","key":"48_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1708-8305.2010.00448.x","volume":"17","author":"JA Al-Tawfiq","year":"2010","unstructured":"Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med. 2010;17(Suppl):3\u20138.","journal-title":"J Travel Med."},{"issue":"1","key":"48_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144-166.2000","volume":"13","author":"M Deuren van","year":"2000","unstructured":"van Deuren M, Brandtzaeg P, van Der Meer J, et al. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144\u201366.","journal-title":"Clin Microbiol Rev."},{"issue":"7","key":"48_CR7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1586\/erv.11.90","volume":"10","author":"KA Bryant","year":"2011","unstructured":"Bryant KA, Marshall GS. Haemophilus influenzae type b\u2013Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011;10(7):941\u201350.","journal-title":"Expert Rev Vaccines."},{"issue":"3","key":"48_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","volume":"9","author":"A Khatami","year":"2010","unstructured":"Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9(3):285\u201398.","journal-title":"Expert Rev Vaccines."},{"issue":"2","key":"48_CR9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","volume":"50","author":"AC Cohn","year":"2010","unstructured":"Cohn AC, MacNeil JR, Harrison LH. Changes in Neisseria meningitidis disease epidemiology in the United States 1998\u20132007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184\u201391.","journal-title":"Clin Infect Dis."},{"issue":"18","key":"48_CR10","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","volume":"29","author":"LH Harrison","year":"2011","unstructured":"Harrison LH, Pelton SI, Wilder-Smith A, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363\u201371.","journal-title":"Vaccine."},{"issue":"2","key":"48_CR11","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","volume":"50","author":"LH Harrison","year":"2010","unstructured":"Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(2):S37\u201344.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"48_CR12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.vaccine.2006.11.018","volume":"25","author":"WP Hausdorff","year":"2007","unstructured":"Hausdorff WP, Hajjeh R, Al-Mazrou A, et al. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region\u2014current status and needs. Vaccine. 2007;25(11):1935\u201344.","journal-title":"Vaccine."},{"issue":"Suppl. 2","key":"48_CR13","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl. 2):B51\u201363.","journal-title":"Vaccine."},{"key":"48_CR14","unstructured":"GlaxoSmithKline. GSK Receives FDA Approval for MenHibrix. 2012. http:\/\/us.gsk.com\/html\/media-news\/pressreleases\/2012\/2012-pressrelease-1134018.htm . Accessed 22 Mar 2013."},{"issue":"3","key":"48_CR15","first-page":"5","volume":"15","author":"GS Marshall","year":"2012","unstructured":"Marshall GS. Perspectives on immunization. J Manag Care Med. 2012;15(3):5\u201310.","journal-title":"J Manag Care Med."},{"issue":"2","key":"48_CR16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/315284","volume":"181","author":"P Richmond","year":"2000","unstructured":"Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181(2):761\u20134.","journal-title":"J Infect Dis."},{"issue":"1","key":"48_CR17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","volume":"19","author":"LH Harrison","year":"2006","unstructured":"Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142\u201364.","journal-title":"Clin Microbiol Rev."},{"issue":"3","key":"48_CR18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","volume":"178","author":"DM Granoff","year":"1998","unstructured":"Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178(3):870\u20134.","journal-title":"J Infect Dis."},{"issue":"1","key":"48_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tmaid.2009.12.001","volume":"8","author":"M Broker","year":"2010","unstructured":"Broker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis. 2010;8(1):47\u201350.","journal-title":"Travel Med Infect Dis."},{"key":"48_CR20","doi-asserted-by":"crossref","unstructured":"Miller JM, Mesaros N, Van Der Wielen M, et al. Conjugate meningococcal vaccines development: GSK biologicals experience. Adv Prev Med. 2011;Article ID 846756.","DOI":"10.4061\/2011\/846756"},{"key":"48_CR21","unstructured":"Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report (MMWR). 2011;60:72\u20136."},{"issue":"18","key":"48_CR22","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","volume":"72","author":"J Croxtall","year":"2012","unstructured":"Croxtall J, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (NimenrixTM). Drugs. 2012;72(18):2407\u201330.","journal-title":"Drugs."},{"issue":"6","key":"48_CR23","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1542\/peds.2009-2992","volume":"127","author":"KA Bryant","year":"2011","unstructured":"Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C\/Y conjugate vaccine in infants. Pediatrics. 2011;127(6):e1375\u201385.","journal-title":"Pediatrics."},{"key":"48_CR24","unstructured":"GlaxoSmithKline. US prescribing information for MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) 2012. http:\/\/us.gsk.com\/products\/assets\/us_menhibrix.pdf . Accessed 22 Mar 2013."},{"key":"48_CR25","unstructured":"Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52\u20134."},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","journal-title":"J Exp Med."},{"key":"48_CR27","doi-asserted-by":"crossref","unstructured":"Robbins JB, Parke JC, Schneerson R, et al. Quantitative measurement of \u201cnatural\u201d and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 1973;7:103\u201310.","DOI":"10.1203\/00006450-197303000-00001"},{"key":"48_CR28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1542\/peds.60.5.730","volume":"60","author":"H Peltola","year":"1977","unstructured":"Peltola H, K\u00e4ythy H, Sivonen A, et al. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3\u00a0months to 5\u00a0years of age in Finland. Pediatrics. 1977;60:730\u20137.","journal-title":"Pediatrics."},{"key":"48_CR29","doi-asserted-by":"crossref","unstructured":"Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149:1034\u20135.","DOI":"10.1093\/infdis\/149.6.1034"},{"key":"48_CR30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","volume":"147","author":"H K\u00e4ythy","year":"1983","unstructured":"K\u00e4ythy H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.","journal-title":"J Infect Dis."},{"issue":"51","key":"48_CR31","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1016\/j.vaccine.2007.10.013","volume":"25","author":"T Nolan","year":"2007","unstructured":"Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b\u2013Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25(51):8487\u201399.","journal-title":"Vaccine."},{"issue":"3","key":"48_CR32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/INF.0b013e3181fcb2bf","volume":"30","author":"T Nolan","year":"2011","unstructured":"Nolan T, Richmond P, Marshall H, et al. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2011;30(3):190\u20136.","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"48_CR33","first-page":"640","volume":"6","author":"P Habermehl","year":"2010","unstructured":"Habermehl P, Leroux-Roels G, Sanger R, et al. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4\u00a0months schedule with a fourth dose at 12\u201318\u00a0months of age. Hum. 2010;6(8):640\u201351.","journal-title":"Hum."},{"issue":"1","key":"48_CR34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0b013e3181c3ce88","volume":"29","author":"CD Marchant","year":"2010","unstructured":"Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2010;29(1):48\u201352.","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"48_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e3181cdd379","volume":"29","author":"GS Marshall","year":"2010","unstructured":"Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15\u00a0months of age. Pediatr Infect Dis J. 2010;29(5):469\u201371.","journal-title":"Pediatr Infect Dis J."},{"key":"48_CR36","unstructured":"Marshall GS, Mesaros N, Aris E, et al. Persistence of immunity three years after an investigational haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y tetanus toxoid (HibMenCY-TT) conjugate vaccine (abstract no. 25219). In: Proceedings of the 45th National Immunization Conference, Washington, DC; 28\u201331 Mar 2011."},{"key":"48_CR37","doi-asserted-by":"crossref","unstructured":"Marshall G, Blatter M, Marchant C, et al. Antibody persistence for up to 5\u00a0years after a fourth dose of Haemophilus influenzae type B and Neisseria Meningitidis serogroups C and Y-Tetanus Toxoid conjugate vaccine (Hibmency-TT) given at 12\u201315\u00a0months. Pediatr Infect Dis J. 2013. doi: 10.1097\/INF.0b013e3182840e35 .","DOI":"10.1097\/INF.0b013e3182840e35"},{"issue":"2","key":"48_CR38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4161\/hv.7.2.14170","volume":"7","author":"GS Marshall","year":"2011","unstructured":"Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Human Vaccines. 2011;7(2):258\u201364.","journal-title":"Human Vaccines."},{"issue":"8","key":"48_CR39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4161\/hv.20357","volume":"8","author":"KA Bryant","year":"2012","unstructured":"Bryant KA, McVernon J, Marchant CD, et al. Immunogenicity and safety of measles\u2013mumps\u2013rubella and varicella vaccines coadminstered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis subgroups C and T-tetanus toxoid conjugate vaccine in toddlers. Human Vaccines Immunother. 2012;8(8):1036\u201341.","journal-title":"Human Vaccines Immunother."},{"issue":"3","key":"48_CR40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4161\/hv.18569","volume":"8","author":"S Rinderknecht","year":"2012","unstructured":"Rinderknecht S, Bryant K, Nolan T, et al. The safety profile of Haemophilus influenzae type b\u2013Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Human Vaccines Immunother. 2012;8(3):294\u2013301.","journal-title":"Human Vaccines Immunother."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0048-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0048-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T04:11:42Z","timestamp":1644984702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0048-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0048-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}